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The FNIP co-chaperones decelerate the Hsp90
chaperone cycle and enhance drug binding
Mark R. Woodford1,2, Diana M. Dunn1,2,3, Adam R. Blanden2,3, Dante Capriotti1,2, David Loiselle4,
Chrisostomos Prodromou5, Barry Panaretou6, Philip F. Hughes4, Aaron Smith4, Wendi Ackerman7,
Timothy A. Haystead4, Stewart N. Loh2,3, Dimitra Bourboulia1,2,3, Laura S. Schmidt8,9, W. Marston Linehan9,
Gennady Bratslavsky1,2 & Mehdi Mollapour1,2,3
Heat shock protein-90 (Hsp90) is an essential molecular chaperone in eukaryotes involved in
maintaining the stability and activity of numerous signalling proteins, also known as clients.
Hsp90 ATPase activity is essential for its chaperone function and it is regulated by
co-chaperones. Here we show that the tumour suppressor FLCN is an Hsp90 client protein
and its binding partners FNIP1/FNIP2 function as co-chaperones. FNIPs decelerate the
chaperone cycle, facilitating FLCN interaction with Hsp90, consequently ensuring FLCN
stability. FNIPs compete with the activating co-chaperone Aha1 for binding to Hsp90, thereby
providing a reciprocal regulatory mechanism for chaperoning of client proteins. Lastly,
downregulation of FNIPs desensitizes cancer cells to Hsp90 inhibitors, whereas FNIPs
overexpression in renal tumours compared with adjacent normal tissues correlates with
enhanced binding of Hsp90 to its inhibitors. Our ﬁndings suggest that FNIPs expression can
potentially serve as a predictive indicator of tumour response to Hsp90 inhibitors.
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T
he molecular chaperone heat shock protein-90 (Hsp90) is
responsible for folding, stability and activity of many
proteins also known as ‘client proteins’, including many
responsible for tumour initiation, progression and metastasis1.
This makes the chaperone Hsp90 an attractive target for cancer
therapy2. Hsp90 has the ability to bind and hydrolyse ATP, which
is essential for its chaperone function3. Small molecule inhibitors
bind to the ATP-binding pocket of Hsp90 and inhibit its
chaperone function. Consequently, this prevents Hsp90
interaction with client proteins, leading to their degradation by
the proteasome. In contrast to other anticancer drugs, Hsp90
inhibitors simultaneously inhibit multiple drivers of oncogenesis.
Hsp90 chaperone cycle is tightly regulated by another group of
proteins referred to as ‘co-chaperones’. Their stability does not
depend on Hsp90 function but they interact with distinct Hsp90
conformational states, providing directionality to the Hsp90
cycle4. Furthermore, certain co-chaperones, such as HOP and
Cdc37p50 inhibit the Hsp90 chaperone cycle, assisting in delivery
of distinct sets of client proteins (steroid hormone receptors and
kinases, respectively) to the Hsp90 chaperone machine. In
contrast, the co-chaperone Aha1 facilitates energy-intensive
conformational changes necessary to establish Hsp90 ATPase
competence, markedly increasing the weak endogenous ATPase
activity of Hsp90. Aha1 is thus considered to be a crucial
component of active Hsp90 chaperone complexes5,6.
Here we show that the stability of the tumour suppressor
folliculin (FLCN) depends on the chaperone function of Hsp90.
Germline mutations and loss of function of FLCN causes Birt–
Hogg–Dube´ syndrome, a rare inherited cancer syndrome that
predisposes affected individuals to develop kidney tumours,
pulmonary cysts and benign skin tumours (ﬁbrofolliculomas)7.
FLCN interacts and forms a complex with folliculin-interacting
proteins 1 and 2 (FNIP1 and FNIP2, also referred to as FNIPs)8–10.
The function of FNIPs, however, remains elusive. Our results
indicate that FNIPs act as co-chaperones of Hsp90. They inhibit
its ATPase activity, ‘tailoring’ Hsp90 to chaperone kinase and
non-kinase clients. We have further shown that Aha1
co-chaperone can displace FNIPs and stimulate Hsp90 ATPase
activity. Finally, FNIPs also enhance the binding of Hsp90 to its
inhibitors such as ganetespib (GB); therefore, overexpression of
FNIPs in speciﬁc tumours can be an indicator of their response to
Hsp90 inhibitors.
Results
FLCN is a new client of Hsp90. To determine the binding
partners of the tumour suppressor FLCN, we transiently
expressed an amino-terminally FLAG-tagged FLCN (FLAG–
FLCN) in human embryonic kidney 293 (HEK293) cells and
identiﬁed its intracellular binding proteins by immunoprecipi-
tating FLAG–FLCN with anti-FLAG M2 afﬁnity gel and mass
spectrometry (MS) analysis (Fig. 1a and Supplementary Table 1).
We found molecular chaperones heat shock protein-70 (Hsp70)
and Hsp90, and their regulators HOP, CHIP and Aha1, and
CCT2, CCT4, CCT7 and CCT8, which are members of the cha-
peronin system TRiC (TCP-1 ring complex), (Fig. 1a). We vali-
dated our data by immunoprecipitating the endogenous FLCN
(Fig. 1b) or the FLAG–FLCN (Fig. 1c) from HEK293 cells and
showed its interaction with the molecular chaperone machineries
Hsp70, Hsp90 and a subunit of the chaperonin TRiC, CCT2
(Fig. 1b,c). We also observed FLCN interaction with the Hsp70
and Hsp90 co-chaperones including HOP, CHIP, Cdc37p50, PP5,
p23 and Aha1 (Fig. 1b,c). In general, molecular chaperones are
involved in folding and stability of proteins. We ﬁrst treated the
HEK293 cells with the Hsp70 inhibitor JG-98 (ref. 11) and
showed the degradation of FLCN after a 2 h treatment in both
soluble and insoluble protein fractions (Fig. 1d). These data
suggest that inhibition of Hsp70 does not lead to an increase in
misfolded FLCN but instead to its degradation. The molecular
chaperone Hsp90 however is more selective towards its ‘client
proteins’ and is also involved in protecting them from
degradation12. Therefore, we treated the HEK293 cells with
different inhibitors of Hsp90 such as GB13 (Fig. 1e), SNX2112
(ref. 14) and PU-H71 (ref. 15) (Supplementary Fig. 1a,b), to
evidence the degradation of FLCN. Previous works have shown
that inhibition of Hsp90 generally leads to ubiquitination and
degradation of its client proteins in the proteasome16. We
investigated this possibility by ﬁrst demonstrating that inhibition
of Hsp90 causes its dissociation from FLCN (Fig. 1f). We further
showed that HEK293 cells treated with 50 nM proteasome
inhibitor bortezomib for 2 h before addition of GB blocked
FLCN degradation (Fig. 1g). We did not obtain similar results
when we treated the cells with the lysosomal inhibitor
Baﬁlomycin A1 (Supplementary Fig. 1c), suggesting that the
lysosome is not involved in degradation of FLCN. We next
immunoprecipitated and salt-stripped (with 0.5M NaCl)
FLAG–FLCN from HEK293 cells treated with either 50 nM
bortezomib or 1 mM GB for 4 h and showed its ubiquitination
by western blotting (Fig. 1h). Taken together, our results suggest
that FLCN is a client of Hsp70 and Hsp90. Inhibition of Hsp90
leads to ubiquitination and degradation of FLCN in the
proteasome.
FNIP1 and FNIP2 facilitate FLCN binding to Hsp90 chaperone.
FNIP1 and FNIP2 are homologous binding partners of FLCN8,10;
however, their molecular function remains elusive. In addition,
FNIP1 was shown to interact with Hsp90, but the signiﬁcance
of this observation was not researched further8. We ﬁrst
conﬁrmed these data by immunoprecipitating the endogenous
FNIP1 and FNIP2 from HEK293 cells and detecting Hsp90
(Fig. 2a). We also observed FNIPs interaction with Hsp70 and
co-chaperones p23, HOP and Cdc37p50 (Fig. 2a). In addition,
we co-immunoprecipitated Hsp90 clients such as glucocorticoid
receptor (GR), B-Raf, Cdk4 and FLCN (Fig. 2a). We conﬁrmed
our data by transiently expressing and immunoprecipitating
HA–FNIP1 and HA–FNIP2 from HEK293 cells and then
probing for the chaperones, co-chaperone and client proteins
(Supplementary Fig. 2a). Previous work has shown that FNIPs
are homo- and heterodimer proteins10. We isolated FNIP1
and FNIP2 homo- and heterodimers by transiently
co-expressing cMyc–FNIP1/HA–FNIP1, cMyc–FNIP2/HA–
FNIP2 and HA–FNIP1/cMyc–FNIP2 in HEK293 cells. We ﬁrst
immunoprecipitated cMyc-tagged proteins using anti-cMyc
agarose afﬁnity gel. We then competed the cMyc proteins from
the afﬁnity gel with cMyc peptides. The eluted proteins were
dialysed and subjected to a second round of immunoprecipitation
(IP) using anti-HA agarose afﬁnity gel. Immunoprecipitated
proteins have shown that FNIP1 homodimer has a stronger
afﬁnity for binding to Hsp90 and FLCN than FNIP2 (Fig. 2b).
We next asked whether FNIP1 or FNIP2 are clients or
co-chaperones of Hsp90. Treating HEK293 cells with the Hsp90
inhibitor GB did not affect FNIP protein stability (Fig. 2c). These
data suggest that FNIP1 and FNIP2 are co-chaperones of Hsp90.
We obtained further evidence by demonstrating a direct
interaction between FNIP1 and Hsp90. We were able to
bacterially express and purify a small amount of FLAG–FNIP1.
Our puriﬁed FLAG–FNIP1 can directly interact with bacterially
expressed and puriﬁed Hsp90a–His6 (Fig. 2d) and FLCN–His6
(Fig. 2e). Surprisingly, Hsp90a and FLCN did not directly interact
with each other in vitro; however, pre-incubation of Hsp90a
with FNIP1 facilitated the Hsp90–FNIP1–FLCN complex
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formation (Fig. 2f). It is noteworthy that we were unable to
express and purify an adequate amount of FNIP2 protein from
bacteria, yeast or baculovirus expression systems for biophysical
analysis.
Hsp90 consists of N (amino), M (middle) and C (carboxy)
domains. To determine FNIP and FLCN interaction with these
Hsp90 domains, we transiently expressed each domain with
FLAG-tag in HEK293 cells. Following IP with anti-FLAG M2
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Figure 1 | Folliculin is a new client of Hsp90. (a) FLAG–FLCN was expressed and isolated from HEK293 cells. Proﬁle of interacting proteins determined by
MALDI–time of ﬂight. Red nodes represent chaperones and co-chaperones, blue nodes are chaperonins and green nodes are splicing factors and ribosomal
proteins. (b) FLCN was isolated from HEK293 cell lysates using anti-FLCN or IgG (control) and immunoblotted with indicated antibodies to conﬁrm protein
interactions. (c) HEK293 cells were transiently transfected with FLAG–FLCN or empty vector control (EV), immunoprecipitated and immunoblotted with
indicated antibodies to conﬁrm interacting proteins. (d) HEK293 cells were treated with 10mM of the Hsp70 inhibitor JG-98 at the indicated time points.
FLCN protein stability in soluble and insoluble fraction was assessed by immunoblotting. (e) HEK293 cells were treated with 1 mM GB at the indicated time
points. FLCN protein stability was assessed by immunoblotting. Akt and Phospho-S473-Akt were used as positive controls. (f) Hsp90a–FLAG was
transiently expressed in HEK293 cells. Cells were treated with 1 mM GB for the indicated times. Hsp90a–FLAG was immunoprecipitated and co-IP of FLCN
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protein levels were evaluated at the indicated time points by immunoblotting (upper blots). HEK293 cells were also treated with 1 mM GB for 1 h before
addition of 50 nM BZ. Immunoblotting was used to evaluate the FLCN level for the indicated time points (lower blots). (h) Empty vector (EV) or FLAG–
FLCN was used to transiently transfect HEK293 cells for 24 h then treated for 4 h with either 50 nm BZ or 1 mM GB. FLAG–FLCN was immunoprecipitated
and ubiquitination was examined by immunoblotting with a pan-anti-ubiquitin antibody.
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afﬁnity gel, we observed FNIP1 interaction with the Hsp90a
M- and C-domains, whereas FNIP2 interacted with only the
M-domain of Hsp90a (Fig. 3a). Association of FLCN with the M-
and C-domains of Hsp90a was also observed (Fig. 3a).
We next determined the region in FNIP1 that interacts with
Hsp90. FNIP1 does not have a known functional domain;
however, based on previous studies8,10, we constructed and
transiently expressed four regions of HA–FNIP1 designated A–D
in HEK293 cells (Fig. 3b). Consistent with the previous work8,10,
truncation of FNIP1 at the C-terminus (deletion of fragment D)
abrogated its interaction with FLCN (Fig. 3b). However, the
concomitant deletion of 300 amino acids (fragment A) from
the N-terminus of FNIP1 restored its binding to FLCN (Fig. 3b).
This result is not in agreement with the previous study8 and
underlies the complexity in FNIP1 binding to FLCN. Our data
also indicated that the C-domain of FNIP1 (amino acid
929–1166 or fragment D) preferentially interacts with Hsp90
(Fig. 3b). We conﬁrmed these data by carrying out a reciprocal
experiment and co-expressing FNIP1-D–HA and Hsp90a–FLAG
full-length (wild type) and its different domains in HEK293 cells.
We immunoprecipitated FNIP1-D–HA and observed co-IP
of Hsp90a full length and its M-domain (Fig. 3c). We next
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bacterially expressed and puriﬁed fragment D (FNIP1-D–His6),
(Supplementary Fig. 2b,c) and examined its afﬁnity for binding to
Hsp90a in vitro by ﬂuorescently labelling FNIP1-D–His6 with
Texas Red Maleimide, and measured the Kd by ﬂuorescence
anisotropy (Fig. 2j). Our bacterially expressed and puriﬁed
HSP90a had ATPase activity. The titration ﬁt to a single-site
binding equation with a Kd of 1.3±0.7 mM (Fig. 3d). This Kd was
unaffected by the presence, absence or identity of adenosine
nucleotide bound to the protein (Supplementary Fig. 2d). Taken
together, our ﬁndings suggest that FNIPs behave as co-
chaperones of Hsp90 and they are involved in loading of FLCN
to Hsp90.
FNIPs regulate Hsp90 activity and chaperoning of the clients.
To gain further insight into FNIP1 and FNIP2 function as
co-chaperones of Hsp90, we used small interfering RNA (siRNA)
to silence either FNIP1 or FNIP2 (Supplementary Table 2), or
both in HEK293 cells, and monitored the stability and activity of
the Hsp90 kinase clients such as B-Raf, Ulk1 and Cdk4, and non-
kinase clients, for example, GR, ER and FLCN (Fig. 4a and
Supplementary Fig. 3a). Silencing either FNIP1 or FNIP2 caused a
modest decrease in client protein levels. This data suggests that
the absence of either FNIP1 or FNIP2 allows for compensation by
the other FNIP isoform. Silencing of both FNIP1 and FNIP2
signiﬁcantly decreased the stability of the selected kinase and
Input 
Total 
IP 
EV N M C WT 
Hsp90α–FLAG
Co–IP
HA-FNIP1-D
GAPDH
HA-FNIP1-D
IP:HA
IgG
H
sp
90
α
−
FL
AG
c 
N CM
1 284 620 732
Hsp90α
M
N C M 
M 
N 
C 
FLCN
GAPDH
FNIP1
FNIP2
Input 
IP 
EV N M C 
Hsp90α domains 
IP:FLAG
Total 
H
sp
90
α
−
FL
AG IgG
d 
An
is
ot
ro
py
0 1 2 3 4 5
0.21
0.18
0.15
Input 
GAPDH
FLCN
Hsp90
H
A–
FN
IP
1
IP 
Input 
Co–IP
Co–IP
Input 
Co–IP
Input 
Co–IP
Co–IP
IP:HA EV FN
IP1
AB
C
BC
D
CD C DAB BC
Total 
b
1–1,166 
300–929 
1–602 
1–929 
300–1,166 
A 
a.a.
602–1,166 
602–929 
929–1,166 
B D C 
D 
C 
A B C 
B D C 
B C 
D C 
A B 
72 
72 
130 
130 
130 
130 
36 
55 
36 
28 
17 
95 
95 
72 
72 
36 
55 
95 
36 
130 
28 
72 
36 
36 
17 
28 
36 
55 
72 
95 
17 
28 
36 
55 
95 
72 
kDa
kDa
kDa
kd=1.3 ± 0.7 μM 
Hsp90α (μM dimer)
a
Figure 3 | FNIPs directly bind to Hsp90 M- and C-domains. (a) FLAG-tagged Hsp90a-N-, M-, and C-domains were transiently expressed and
immunoprecipitated from HEK293 cells. Co-IP of endogenous FLCN and FNIPs were assessed by immunoblotting. Empty vector (EV) was used as a control.
(b) HA-tagged FNIP1 domains were transiently expressed and isolated from HEK293 cells. Co-IP of endogenous FLCN and Hsp90 were assessed by
immunoblotting. Empty vector (EV) was used as a control. (c) FLAG-tagged Hsp90a domains were transiently co-expressed with HA-tagged FNIP1-D in
HEK293 cells. HA–FNIP1-D was immunoprecipitated and Hsp90a–FLAG co-IP was evaluated by immunoblotting. (d) Bacterially expressed and puriﬁed
FNIP1-D and Hsp90a binding afﬁnity measured by ﬂuorescence anisotropy. The error bars represent mean ±s.d. of three independent experiments.
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms12037 ARTICLE
NATURE COMMUNICATIONS | 7:12037 | DOI: 10.1038/ncomms12037 | www.nature.com/naturecommunications 5
non-kinase client proteins (Fig. 4a). We next transiently over-
expressed cMyc–FNIP1 or cMyc–FNIP2 in HEK293 cells and
examined the stability and the activity of the Hsp90 clients.
Overexpression of FNIPs caused an increase in GR, Ulk1 and
FLCN protein levels and hyperphosphorylation of B-Raf and
pY416-c-Src (Fig. 4b and Supplementary Fig. 3b).
Cystic ﬁbrosis transmembrane conductance regulator (CFTR)
is also an Hsp90 client 17,18 and relies on a ‘slow’ Hsp90
chaperone cycle for proper folding. To examine the effect of
FNIPs on Hsp90 chaperone function, we assessed their impact on
steady-state expression of CFTR protein in mammalian cells.
HEK293 cells were transiently co-transfected with CFTR, and
HA–FNIP1 and HA–FNIP2. Empty plasmid pcDNA3 (empty
vector, EV) was used as a negative control. Western blot analysis
of these samples using anti-CFTR antibody detected a doublet
(Fig. 4c), with the upper band representing the mature Golgi-
processed glycoform of CFTR found at the cell surface and the
lower band an immature core-glycosylated protein (Fig. 4c).
Overexpression of the FNIPs produced a signiﬁcant increase in
CFTR protein (Fig. 4c). These data suggested a reduction in
Hsp90 chaperone activity and, therefore, an increase in CFTR
expression.
Hsp90 chaperone function is coupled to its ATPase activity3.
We therefore examined the impact of FNIPs on Hsp90 ATPase
activity. We transiently expressed Hsp90a–HA in the prostate
cancer PC3 cell line and HA–FNIP1, HA–FNIP1-D (amino acids
929–1166) and HA–FNIP2 in HEK293 cells. Proteins were
immunoprecipitated, salt stripped and competed off the HA
afﬁnity beads with the relevant peptides (Supplementary Fig. 4a).
The quality of the isolated proteins was examined by Coomassie
staining of the SDS–polyacrylamide gel electrophoresis (SDS–
PAGE). These puriﬁed proteins were quantiﬁed and used in the
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molar ratio indicated in Supplementary Fig. 4b of Hsp90a:FNIP
in the PiPer Phosphate Assay Kit (Thermo Fisher Scientiﬁc), in
the presence of ATP as substrate as previously described (see
Methods)19. We measured the ATPase activity of isolated Hsp90a
in vitro as previously described19 (Fig. 4d and Supplementary
Fig. 4c). GB (10 mM) inhibited ATPase activity (Fig. 4e). Addition
of FNIP1, FNIP1-D and FNIP2 also signiﬁcantly inhibited the
ATPase activity of Hsp90a (Fig. 4d and Supplementary Fig. 4c).
Percentage ATPase activity was based on mmol Pi per molmin 1
for Hsp90a alone and in the presence of FNIPs titrated until
inhibition was achieved (Hsp90a¼ 291.5 nM, FNIP1¼ 189.8 nM,
FNIP1-D¼ 899.3 nM and FNIP2¼ 1.6 mM) (Supplementary
Fig. 4d). These data suggest that FNIPs are potent inhibitors of
the Hsp90 chaperone cycle.
Hsp90 is an evolutionarily conserved chaperone and based on
structural homology detection methods Lst4 is a potential
orthologue of FNIPs in Saccharomyces cerevisiae20. However, we
were unable to detect Lst4–GST interaction with yeast Hsp90
(yHsp90, also known as Hsp82) (Fig. 5a). In addition, unlike
FNIPs, Lst4–GST was unable to inhibit ATPase activity of yHsp90
in vitro (Fig. 5b and Supplementary Fig. 4e,f). We next decided to
express FLAG–FNIP1 and FLAG–FNIP2 galactose-inducible
promoter of GAL1 in yeast containing either human or yeast
Hsp90 as the sole functional Hsp90. Overexpression of FNIPs in
yeast containing human Hsp90a caused lethality (Fig. 5c).
However, overexpression of FNIPs in yeast with only yHsp90
did not cause any growth defects. We examined the expression
of the FNIPs in these cells by western blot analysis and were
only able to detect FLAG–FNIP1 and FLAG–FNIP2 in yeast
expressing Hsp90a (Fig. 5d). These data suggest that expression of
FNIPs in yeast cause lethality, because they inhibit the essential
chaperone function of Hsp90a. Taken together, our results
suggest that (i) Lst4 is not an orthologue of FNIPs in yeast and
(ii) FNIPs probably arose in higher eukaryotes as co-chaperones to
inhibit or slow the complex chaperone cycle of Hsp90 in cellular
milieu.
FNIPs compete with the Aha1 co-chaperone for binding to Hsp90.
To determine the effects of FNIPs on Hsp90 interaction with
co-chaperones, we used FNIP1- and FNIP2-speciﬁc siRNA to
silence expression of these genes in HEK293 cells transiently
expressing Hsp90a–FLAG. We next immunoprecipitated
Hsp90a–FLAG from these cells and examined its interaction with
selected co-chaperones. Our data show that siRNA-mediated
silencing of both FNIP1 and FNIP2 increased Hsp90 interaction
with the co-chaperones Aha1 and PP5 (Fig. 6a). We next
transiently overexpressed HA–FNIP1 and HA–FNIP2 in HEK293
cells that also express Hsp90a–FLAG. The overexpression
of FNIPs compared with the endogenous FNIP1 and FNIP2
were examined by immunoblotting (Supplementary Fig. 5a).
Following IP of Hsp90a–FLAG, we observed a marked reduction
in its interaction with the co-chaperones Aha1 and PP5
(Fig. 6b). Aha1 is the activator of the Hsp90 ATPase activity5,6.
We next queried whether Aha1 has the ability to stimulate the
ATPase activity of Hsp90 that has already bound to FNIP1,
FNIP1-D or FNIP2. In agreement with our earlier data,
FNIPs inhibited the ATPase activity of Hsp90a and, conversely,
addition of 1.3 mM Aha1 to these reactions stimulated Hsp90
ATPase activity (Fig. 6c and Supplementary Fig. 5b–f). Taken
together, these data suggest that Aha1 has the ability to displace
FNIPs from Hsp90. We obtained additional evidence for this
possibility by using the bacterially expressed and puriﬁed
Hsp90a, Aha1–FLAG and FNIP1-D fragment. First, we bound
FNIP1-D–His6 to Ni-NTA agarose and incubated with 100 ng
recombinant Hsp90a. After washing the agarose with buffer, we
added different amounts of Aha1–FLAG. Our data show that
addition of 10 ng recombinant Aha1–FLAG completely
dissociated Hsp90a from FNIP1-D–His6 (Fig. 6d). We next
carried out a similar experiment by ﬁrst immobilizing
Aha1–FLAG onto anti-FLAG M2 afﬁnity gel. We then added
100 ng recombinant Hsp90a, to form an Aha1–Hsp90a complex.
After washing the agarose beads with buffer, we added different
amounts of FNIP1-D–His6. We observed that addition of 100 ng
FNIP1-D–His6 disrupted the Aha1–Hsp90a complex (Fig. 6e).
We repeated the experiments in Fig. 6d,e, but using bovine serum
albumin as a negative control (Supplementary Fig. 5g–i). Our
data conﬁrm that Aha1 and FNIP1 compete for binding to
Hsp90, either accelerating or decelerating its chaperone cycle. In
addition, Aha1 appears to have higher afﬁnity than FNIP1
c
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towards Hsp90, as 10 ng of Aha1 was sufﬁcient to displace
FNIP1-D from Hsp90 (Fig. 6d).
FNIPs overexpression enhances Hsp90 binding to ATP and
drugs. ATP binding and hydrolysis by the N-terminus of Hsp90
is essential for its chaperone function (Fig. 7a) 3. We examined
the impact of FNIPs on Hsp90 binding to ATP or drugs by ﬁrst
overexpressing HA–FNIP1 and HA–FNIP2 in HEK293 cells.
Overexpression of FNIPs caused an increase in Hsp90 binding to
ATP agarose (Fig. 7b). Furthermore, overexpression of cMyc–
FNIP1 and cMyc–FNIP2 in HEK293 cells signiﬁcantly increased
the Hsp90 binding to 0.01 mM biotinylated-GB (Fig. 7c,d) and
0.01 mM biotinylated-SNX2112 (ref. 14 and Fig. 7e,f) compared
with control (EV). We next examined the effects of FNIP1 and
FNIP2 knockdown on Hsp90 binding to ATP and drug. siRNA
knockdown of FNIP1, FNIP2 or both in HEK293 cells did not
have an impact on Hsp90 binding to ATP (Fig. 7g) but
signiﬁcantly decreased Hsp90 binding to GB (Fig. 7h).
We next conﬁrmed that overexpression of either FNIP1–HA
or FNIP2–HA (Fig. 8a,b) sensitized the HEK293 cells to GB,
as evidenced by induction of the pro-apoptotic markers
cleaved caspase-3 and cleaved poly-ADP-ribose polymerase
(PARP) (Fig. 8c). Conversely, siRNA knockdown of FNIP1 or
FNIP2 in HEK293 cells signiﬁcantly reduced apoptosis with
1 mM GB and knockdown of both FNIPs completely abolished
the induction of apoptotic markers (Fig. 8d). Taken together,
these data suggest that expression of FNIPs correlates to Hsp90
binding to drugs and also sensitivity of cells to Hsp90
inhibitors.
FNIPs overexpression sensitizes cancer cells to Hsp90 drugs.
Tumours are generally sensitive to Hsp90 inhibitors19,21,22.
We therefore asked whether FNIPs are overexpressed in cancer
cells and also whether they are contributing to cancer cell
sensitivity towards Hsp90 inhibitors. We used prostate (LNCaP),
bladder (T24), breast (MCF7), lung (H1299) and colorectal
adenocarcinoma (HT29) cancer cell lines. Previous work by Synta
Pharmaceuticals Corp. (data available at www.syntapharma.com/)
has established these cell lines’ sensitivity to Hsp90 inhibitor
GB and these are: LNCaP (IC50¼ 8 nM), T24 (IC50¼ 7 nM),
MCF7 (IC50¼ 25 nM), H1299 (IC50¼ 6 nM) and HT29
(IC50¼ 50 nM). We ﬁrst showed that FNIPs were highly
expressed in these cancer cells compared with HEK293
cells (Fig. 9a). We next immunoprecipitated the endogenous
Hsp90 from the above cancer cells and detected its interaction
with FNIPs (Fig. 9a). To link the high levels of FNIPs with
sensitivity of cancer cells to Hsp90 inhibitors, we used siRNA to
knock down FNIP1 and FNIP2 in LNCaP, T24, MCF7, H1299
and HT29 cells. The apoptotic markers cleaved caspase-3 and
cleaved PARP were abundant in cancer cells treated with 0.1 mM
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GB; however, this effect was abrogated in the siRNA FNIPs
knockdown samples (Fig. 9b–f). These data suggest that
overexpression of FNIPs is a contributing factor towards cancer
cell sensitivity to Hsp90 inhibitor GB. It is noteworthy that
cleaved caspase-7 was used to evaluate apoptosis in MCF7 cells, as
they lack caspase-3 (Fig. 9d).
Elevated FNIPs sensitize renal tumours to Hsp90 inhibitor. To
gain further insight into FNIPs expression and sensitivity of
tumours to Hsp90 inhibitors, we examined tumours and adjacent
normal tissues from patients with renal cell carcinoma (RCC), the
most common type of kidney cancer23. Histopathologically,
RCCs are classiﬁed into subtypes. We used tumours from patients
with clear cell RCC, papillary type I and type II RCC, and
oncocytoma (Fig. 10a–d). Within 10min of removal of tumours,
by radical or partial nephrectomy, RCC tumours and adjacent
normal tissues were dissected into 3mm3 pieces followed by
protein extraction and drug binding assay. Our data showed that
both FNIP1 and FNIP2 were overexpressed in RCC tumours
compared with adjacent normal tissues (Fig. 10a–d). In addition,
we discovered that the Hsp90 from RCC tumours had a higher
afﬁnity for binding to biotinylated GB compared with the
adjacent normal tissues (Fig. 10a–d). We next showed greater
association between Hsp90 and FNIPs compared with normal
tissues (Fig. 10e). This is not surprising, because FNIPs are highly
expressed in tumours compared with adjacent normal tissues.
However, we found that Hsp90 bound stronger to Aha1 in
normal tissues compared with the tumours, even though both
tissues expressed equal levels of Aha1 (Fig. 10e). Our earlier data
showed that FNIPs compete with the activating co-chaperone
Aha1 for binding to Hsp90 (Fig. 6e). We therefore asked whether
addition of puriﬁed FNIP1-D–His6 to the protein lysates from
normal tissues could disrupt the Hsp90–Aha1 complex. Addition
of 100 ng FNIP1-D–His6 to protein lysates from normal tissues
displaced Aha1 interaction with Hsp90 and also increased Hsp90
binding to 0.1 mM biotinylated GB (Fig. 10f). Taken together, our
data suggest that FNIPs make renal tumours sensitive to Hsp90
inhibitors. Their expression level can potentially serve as a
predictive indicator of tumour response to Hsp90 inhibitors.
Discussion
Germline mutation in the tumour suppressor FLCN is responsible
for Birt–Hogg–Dube´ syndrome, an inherited kidney cancer
syndrome24. Previous work has shown that FNIP1 and FNIP2
are critical components of the FLCN complex and are essential
for its tumour suppressive function9. However, the exact
molecular function of FNIP1 and FNIP2 remains elusive. In
this study, we demonstrate by MS analysis that FLCN interacts
with the molecular chaperones Hsp70 and Hsp90, as well as
members of the chaperonin system TRiC. Our data have shown
that FLCN is a bona ﬁde Hsp70 and Hsp90 client, as treating the
cells with the Hsp70 inhibitor JG-98 destabilizes FLCN, and
furthermore Hsp90 inhibitor treatment GB, SNX2112 or PU-H71
leads to dissociation of FLCN from Hsp90 and consequently its
ubiquitination and proteasomal degradation. Based on our
current knowledge in the function of TRiC–Hsp70–Hsp90
proteins and also our ﬁndings here, we would like to suggest
that TRiC-Hsp70 are involved in ‘early’ stages of FLCN folding
and Hsp90 plays a key role in protecting FLCN from degradation.
We further demonstrated that FLCN binding partners FNIP1 and
FNIP2 function as co-chaperones of Hsp90. FNIP1 interacts with
the M- and C- domains of Hsp90, whereas FNIP2 interacts only
with its M- domain. Previous work reported that FNIP1 and
FNIP2 exist as a homodimer and a heterodimer, respectively10.
We conﬁrmed these data by demonstrating the existence of a
FNIP1:FNIP2 heterodimer and its interaction with FLCN. We
have also demonstrated that three populations of FNIP1 and
FNIP2 interact with Hsp90; however, the FNIP1 homodimer
preferentially binds to Hsp90. Our in vitro data provide
additional evidence that recombinant FNIP1 directly interacts
with Hsp90; however, FLCN requires the presence of FNIP1 for
its binding to Hsp90. These data suggest that FNIP1 and FNIP2,
similar to the co-chaperone Cdc37, are involved in ‘loading’ of
FLCN and perhaps other client proteins to Hsp90. Approximately
93% of all pathogenic FLCN mutations prematurely truncate the
encoded FLCN protein25. When experimentally modelled
in vitro, most mutations analysed appeared to be pathogenic by
disrupting stability of FLCN25. In addition, FLCN binding to both
FNIP1 and FNIP2 is mediated speciﬁcally through the C-terminal
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region of FLCN8,26. Truncating mutations result in loss of the
C-terminus of FLCN, abolishing its interaction with FNIP1 and
FNIP2, and consequently Hsp90. We speculate that loss of Hsp90
interaction with FLCN is the reason for the instability of the
pathogenic FLCN mutants.
Hsp90 chaperone activity is coupled to its ATPase activity,
which is tightly regulated by co-chaperones and posttranslational
modiﬁcation27,28. Our results suggest that FNIP1 is a potent
inhibitor of Hsp90 ATPase activity, as 200 nM of FNIP1 inhibits
Hsp90 ATPase activity by 50-fold. FNIP2 also has shown
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inhibitory activity towards Hsp90; however, it required 1.6 mM of
FNIP2 to inhibit the ATPase activity by eightfold. Although we
use the term ‘inhibition’ here, FNIPs seem only to be slowing the
chaperone cycle. Their effect on Hsp90 is not similar to the small
molecule inhibitors of Hsp90 that bind to the N-domain and
inhibit Hsp90 chaperone function. The reason for this conclusion
stems from our observation that overexpression of FNIP1 or
FNIP2 does not lead to degradation of Hsp90 client proteins.
In addition, chaperoning of the proteins such as CFTR that
require a slow chaperone cycle was enhanced by overexpression
of FNIP1 and FNIP2. We have also shown that overexpression of
FNIPs enhance Hsp90 binding to GB and SNX2112. Moreover,
Hsp90 from kidney tumours bound stronger to GB compared
with Hsp90 from adjacent normal tissues. This observation
correlated with the overexpression of both FNIP1 and FNIP2 in
tumours compared with adjacent normal tissues. Our ﬁndings
suggest that FNIPs expression level can potentially serve as a
predictive indicator of tumour response to Hsp90 inhibitors.
What is the relationship between FNIPs and Aha1 towards
binding to Hsp90? FNIPs bind to the M-domain of Hsp90 and
may interfere with the N-domain interaction with the catalytic
domain. We also found that FNIPs compete with Aha1 co-
chaperone binding to Hsp90. Our data have demonstrated the
ability of FNIP1 and Aha1 to compete for binding to Hsp90, ﬁne
tuning its chaperone cycle. The competition between Aha1 and
FNIPs binding to Hsp90 was also observed in renal tumours and
their adjacent normal tissues. We found that Aha1 bound
stronger to Hsp90 in normal tissues; however, overexpression of
FNIPs appears to displace Aha1 from Hsp90 and increase Hsp90
binding to its inhibitors. Our data are in agreement with
previously published work by Workman’s laboratory29,
suggesting that Aha1 dissociation from Hsp90 plays a role in
drug sensitivity. What determines the binding of these proteins to
Hsp90? We have already shown that posttranslational
modiﬁcations of Hsp90 determine its binding to co-
chaperones28. In addition, our recent work has shown that
c-Abl-mediated phosphorylation of Y223-Aha1 promotes its
interaction with Hsp90 (ref. 19). We therefore suspect similar
mechanisms exist between these three proteins, where cross-talk
between posttranslational modiﬁcations is a determining factor
for differential binding of Aha1 and FNIPs to Hsp90.
Methods
Plasmids and yeast strains. FLCN complementary DNA was
synthesized in FLAG-tagged pcDNA3.1 vector backbone
(Thermo Fisher Scientiﬁc) by GeneWiz, Inc. FNIP1–His6 and
FNIP2–His6 messenger RNA was also synthesized in pcDNA3.1
by GeneWiz, Inc. and subcloned into pCMV-Myc and pCMV–
HA vectors (ClonTech). The EVs containing these tags were used
and also referred to as controls. For bacterial expression of
FNIP1, FNIP2, FNIP1-D and Hsp90a, pRSET-A expression
vector containing a 6 His tag (ThermoFisher Scientiﬁc) was
used. The HA–FNIP1 domain-speciﬁc plasmids were previously
reported8. Hsp90a domain-speciﬁc plasmids were ampliﬁed using
primers listed in Supplementary Table 3. FNIP1–FLAG and
FNIP2–FLAG were cloned in to yeast expression plasmid pYES2
using primers FNIP1–KpnI–FLAG–F/FNIP1–XhoI–R and
FNIP2–KpnI–FLAG–F/FNIP2–XhoI–R.
Yeast growth media. Yeast cells were grown on YPDA (2% (w/v)
Bacto peptone, 1% yeast extract, 2% glucose and 20mg per litre
adenine) and YPGal (2% (w/v) Bacto peptone, 1% yeast extract,
2% galactose and 20mg per litre adenine). Selective growth was
on dropout 2% glucose (DO) medium with appropriate amino
acids30. Medium pH was adjusted to 6.8 with NaOH before
autoclaving. The yeast strain pp30 (MAT a, trp1-289, leu2-3,112,
his3-200, ura3-52, ade2-101, lys2-801, hsc82KANMX4 and
hsp82KANMX4) expressing Hsp82-Ycplac111 or Hsp90a-
Ycplac111 as the sole Hsp90 were used in this study. These
yeast strains were reported previously by Mollapour et al.31.
Glutathione S-transferase (GST)-tagged Lst4 under control of the
GAL1/10 promoter expressed in a BY4741 (MATa) background
was acquired from GE Dharmacon.
Mammalian cell culture. Cultured cell lines human embryonic
kidney (HEK293) grown in DMEM (Sigma-Aldrich), human
bladder (T24) and human colorectal adenocarcinoma (HT29)
grown in McCoy’s 5a medium (Sigma-Aldrich), human prostate
cancer (LNCaP) and human non-small cell lung cancer (H1299)
grown in RPMI 1640 medium (Sigma-Aldrich) and human breast
adenocarcinoma (MCF7) grown in Eagle’s minimum essential
medium (Sigma-Aldrich). Cultured cell lines were acquired from
(American Type Culture Collection) and their media was sup-
plemented with 10% fetal bovine serum (Sigma-Aldrich) and
grown in a CellQ incubator (Panasonic Healthcare) at 37 C in an
atmosphere containing 5% CO2.
Ex vivo culture and analysis of human RCC tumours. Tumour
and adjacent normal tissues of the patients with conventional
RCC were obtained with written informed consent from the
Department of Urology at SUNY Upstate Medical University. At
the time of radical or partial nephrectomy, which was done with
o10min of renal ischaemia, RCC tumours were dissected into
B3mm3 pieces and protein was extracted and quantiﬁed as
previously described in detail22.
Bacterial expression and puriﬁcation of proteins. All proteins
were expressed in Escherichia coli strain BL21 (DE3) and included
an N-terminal 6 His tag. Puriﬁcation buffers included
20–50mM Tris or phosphate pH 8.0 and 10mM b-mercap-
toethanol. Chromatography resins were purchased from GE
Healthcare Bio-Sciences (Marlborough, MA), except for Ni-NTA
agarose, which was purchased from Qiagen (Valencia, CA).
Transformed cells were grown at 37 C in lysogeny broth (LB)
with 50mg l 1 ampicillin until OD600¼ 0.6. For Hsp90a, cul-
tures were then cooled to 20 C and induced with 20mg l 1
isopropyl-b-D-thiogalactoside overnight. Cells were harvested by
centrifugation and lysed enzymatically. Hsp90a expressed in the
supernatant and was isolated by sequential Ni-NTA metal afﬁnity
(10–250mM imidazole step gradient), Q-Sepharose anion
exchange (0–1M NaCl gradient) and Superdex-75 size-exclusion
chromatography. Puriﬁed Hsp90a was nucleotide free evidenced
by an A280/260 ratio of 1.83. For FNIP1-D, cells were induced with
20mgl  1 isopropyl-b-D-thiogalactoside at 37 C for 3 h, har-
vested by centrifugation and lysed by sonication. FNIP1-D
expressed in inclusion bodies and was puriﬁed by washing the
pellet 3 in buffer, dissolving the pellet in 8M urea, subjecting
the dissolved pellet to Ni-NTA metal afﬁnity chromatography
(10–250mM imidazole step gradient) and refolding by rapid
dilution. Proteins were 490% pure. Concentrations were deter-
mined using calculated extinction coefﬁcients as previously
described19. Proteins were ﬂash frozen on dry ice and stored at
 80C until use.
Immunoprecipitation and immunoblotting. For IP, mamma-
lian cell lysates were incubated with anti-FLAG antibody con-
jugated beads (Sigma) for 2 h at 4 C. Pulldowns were achieved by
incubating lysate with Ni-NTA agarose (Qiagen) for 2 h at 4 C or
with anti-Hsp90 antibody (835-16F1, Enzo Life Sciences), or anti-
Hsp82 (yHsp90), FLCN (Cell Signaling), FNIP1 or FNIP2 (NCI)
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for 1 h followed by protein G agarose for 2 h at 4 C. Immuno-
pellets were washed four times with fresh lysis buffer (20mM
HEPES pH 7.0, 100mM NaCl, 1mMMgCl2, 0.1% NP40, protease
inhibitor cocktail (Roche) and PhosSTOP (Roche). Proteins
bound to Ni-NTA agarose were washed with 50mM imidazole in
lysis buffer (20mM Tris-HCl pH 7.5, 100mM NaCl, protease
inhibitor cocktail (Roche) and PhosSTOP (Roche)) and eluted
with either 300mM imidazole in lysis buffer or with 5 Laemmli
buffer. Precipitated proteins were separated by SDS–PAGE and
transferred to nitrocellulose membranes. Co-immunoprecipitated
proteins were detected by immunoblotting with indicated dilu-
tions of antibodies recognizing 1:8,000 FLAG (Cat. A2220, Sigma-
Aldrich); 1:2,000 Tetra-His (Cat. 34670, Qiagen); 1:8,000 Hsp90-
835-16F1 (Cat. ADI-SPA-835), 1:10,000 GAPDH (Cat. ADI-
CSA-335), 1:2,000 p23 (Cat. ADI-SPA-670) (ENZO Life Sci-
ences); 1:20,000 Hsp70 (Cat. SPC-103C/D, StressMarq); 1:1,000
CFTR (Cat. 05-583, Millipore); 1:4,000 FLCN (Cat. 3697), 1:2,000
GR (Cat. 12041), 1:2,000 p-GR-S211 (Cat. 4161), 1:2,000 ERa
(Cat. 13258), 1:1,000 CHIP (Cat. 2080), 1:2,000 Grp94 (Cat.
2104), 1:2,000 cMyc (Cat. 2276), 1:2,000 HA (Cat. 3724), 1:1,000
CCT2 (Cat. 3661), 1:1,000 ULK1 (Cat. 8054), 1:1,000 PP5 (Cat.
2289), p50cdc37 (Cat. 4793), 1:2,000 c-Src (Cat. 2123), 1:2,000 p-c-
Src-Y416 (Cat. 2101), 1:4,000 Akt (Cat. 2967), 1:2,000 p-Akt-S473
(Cat. 4060) and 1:2,000 p60Hop (Cat. 5670), cleaved caspase-3
(Asp175) (Cat. 9664), 1:2,000 cleaved caspase-7 (Asp198)
(Cat. 9491) and 1:2,000 cleaved PARP (Asp214) (Cat. 9544) (Cell
Signalling); 1:4,000 GST (Cat. 374171), 1:4,000 Raf-1 (Cat. sc-133),
1:4,000 Cdk4 (Cat. sc-601) and 1:1,000 Ubiquitin (Cat. sc-8017)
(Santa Cruz Biotechnology); and 1:1,000 Aha1 (Cat. 600-401-974,
Rockland). Antibodies (1:500 FNIP1 and 1:500 FNIP2) were
generated at NCI-NIH. Sba1 and Hsp82 (yHsp90) antibodies
were generated at Institute of Cancer Research, UK. Secondary
antibodies raised against goat (Cat. sc-2020), mouse
(Cat. sc-2005), rabbit (Cat. sc-2004) and rat (Cat. sc-2006) (Santa
Cruz Biotechnology) were used at 1:4,000 dilution. Representative
uncropped western blottings are shown in Supplementary Fig. 6.
Protein labelling and Kd measurements. FNIP1-D protein was
desalted into 50mM Tris pH 7.2, 150mM NaCl and 1mM TCEP
using a PD-10 desalting column and labelled with Texas Red C2
maleimide. Labelling stoichiometry was 0.75 labels/FNIP1-D
using e595¼ 104,000M 1 cm 1 for Texas Red and a correction
factor of 0.26 e595 to account for its absorbance at 280 nm.
Hsp90a at the indicated concentrations was incubated on ice in
50mM Tris pH 7.2, 150mM NaCl, 1mM TCEP, 4mM MgCl2
with or without 1mM ATP, ADP or AMPPNP for 10min, then
incubated with 1 mM labelled FNIP1-D for 30min. Fluorescence
anisotropy was measured using a SpectraMax i3 equipped with
rhodamine ﬂuorescence polarization module (lex\lem¼ 535 nm/
595 nm). Curve ﬁtting was done in KaleidaGraph 4.0.
MS analysis. Visible bands were excised from the gel manually
and cut into small pieces B1mm 1mm. These gel pieces were
destained using 1:1 30-mM potassium ferricyanide:100-mM
sodium thiosulfate for 10min. The destained gel pieces were then
washed with 25mM ammonium bicarbonate and acetonitrile
alternatively for 5min each wash. This cycle of 5min 25mM
ammonium bicarbonate wash followed by 5min acetonitrile wash
was repeated three times. To further prepare the gel pieces for
digestion, the gel pieces were then dehydrated in 100% acetoni-
trile. After removing all acetonitrile, 25ml of porcine trypsin
(Promega) dissolved in 25mM ammonium bicarbonate at a
concentration of 20mgml 1 was added to the gel pieces. The gel
pieces were then kept at room temperature overnight (B12–16 h).
Following digestion, the supernatant was transferred to a second
tube and acetonitrile was added to the gel pieces to complete the
extraction of digested peptides. This extract was added to the ﬁrst
supernatant and this combined solution, containing the extracted
peptides, was frozen and lyophilized. The peptides were resus-
pended in 5 ml of 100:99:1 acetonitrile:water:triﬂuoroacetic acid
immediately before spotting on the matrix-assisted laser deso-
rption/ionization (MALDI) target.
For MALDI analysis, the matrix solution consisted of a-cyano-
4-hydroxycinnamic acid (Aldrich Chemical Co., Milwaukee, WI)
saturating a solution of 1:1:0.01 acetonitrile:25mM ammonium
citrate:trifuoroacetic acid. Approximately 0.15 ml of peptide
solution was spotted on the MALDI target immediately followed
by 0.15 ml of the matrix solution. This combined solution was
allowed to dry at room temperature. MALDI–MS and MS/MS
data were then acquired using the ABSCIEX TOF/TOF 5800
Mass Spectrometer. Resultant peptide mass ﬁngerprint and
peptide sequence data were submitted to the UniProt database
using the Mascot search engine to which relevance is calculated
and scores are displayed.
Hsp90 ATPase activity in vivo. ATPase activity of human
Hsp90a isolated from prostate cancer PC3 cells and its activation
by Aha1 or inhibition by HA–FNIP1, HA–FNIP1-D and HA–
FNIP2 from HEK293 cells were measured as previously descri-
bed19. Cells were transiently transfected with Hsp90a–HA (PC3)
or the Aha1–FLAG, HA–FNIP1, HA–FNIP1-D and HA–FNIP2
constructs (HEK293). Following protein extraction and IP,
protein-bound HA (Sigma) or FLAG (Sigma) afﬁnity beads
were washed ﬁve times in 0.5M NaCl and 1% NP40 buffer.
Proteins were competed off the beads with either HA or FLAG
(Sigma) peptide, at 4 C for 2 h with agitation. Protein was then
concentrated with Amicon Ultra-2ml, 10K centrifugal ﬁlters
(Millipore). Using the Micro BCA Protein Assay Kit (Thermo
Scientiﬁc), protein was quantiﬁed and 1 mg was run on an SDS–
PAGE gel as described previously, to standardize the amount of
protein used in the assay. Assay was performed as described in
the PiPer Phosphate Assay Kit instructions for use (Life
Technologies). Standard curve with linear ﬁt line was created
from 0 to 100 mM ﬁnal concentration reactions. Hsp90a (2.5mg)
and 5 mg of Aha1, FNIP1, FNIP1-D and FNIP2 were added to
each reaction run in triplicate, incubated at 37 C for 1 h, with
1mM ATP as substrate and 10 mM GB was used in drug
reactions. ATP turnover was calculated as mmol Pi per mol
Hsp90a per minute and relative ATPase activity was calculated
from those values, with the value of Hsp90a alone representing
100% activity.
Statistical analysis. The data presented are the representative or
examples of three biological replicates, unless it is speciﬁed. Data
were analysed with unpaired t-test. Asterisks in ﬁgures indicate
signiﬁcant differences (*Po0.05, **Po0.005, ***Po0.0005 and
****Po0.0001). Error bars represent the s.d. or s.e. for three
independent experiments, unless it is indicated.
Data availability. The authors declare that the data supporting
the ﬁndings of this study are available within the article and its
Supplementary Information ﬁles.
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